Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Moving Today?

Why ARWR stock is down today

Arrowhead Pharmaceuticals stock fell 5.80% to $66.57 in early trading on Monday after the release of interim clinical data for its first dual-functional RNAi therapeutic. The stock opened higher but quickly reversed course, reaching a session low of $66.50 before closing the session at $66.63. The decline marked one of the stock’s worst days in over a year, despite the positive data showing significant reductions in key cholesterol markers.

What Happened

The stock’s decline followed the announcement of interim topline clinical data for Arrowhead’s Phase 1/2a study of its dual-functional RNAi therapeutic for mixed hyperlipidemia. The data showed mean maximal reductions of 88% in APOC3, 54% in LDL-C, and 73% in triglycerides. Despite these positive results, the stock struggled as the market appeared to interpret the news as a "sell the news" event. The company also presented at the Morgan Stanley 24th Annual Global Healthcare Conference, but the timing coincided with a broader market selloff and rising 10-year yields, which added pressure to the stock.

What The Data Shows

The stock opened with a 0.7% gap up from the previous close but quickly reversed course, hitting a low near $66.50 by midday. Trading volume was 1.2 million shares, which is 0.6 times the 3-month average, suggesting limited follow-through. Over the past 8 sessions, the stock has fallen 14.5% from $85.40 to $73.04. Meanwhile, sentiment has deteriorated, with the 7-day average at 50/100 compared to a 30-day average of 57/100. Recent insider transactions also showed two directors selling shares totaling $1.2 million in late August.

What To Watch

Arrowhead Pharmaceuticals has no upcoming earnings report scheduled. Investors will likely monitor the breadth of coverage and market reaction to the new clinical data in the coming days.